Skip to content
Clinical Trials – home
Kura Oncology Inc.
Sponsor

Kura Oncology Inc.

United States 4930 Directors Place Suite 500, 92121-3848, United States

About the sponsor

Clinical research in relapsed and/or refractory acute myeloid leukemia and genetically defined AML subtypes, with emphasis on NPM1-mutated and KMT2A-rearranged disease.

  • Relapsed/Refractory AML
  • NPM1-mutated AML
  • KMT2A-rearranged AML
  • MEIS1-associated biology

Interest extends to menin inhibition and combination approaches in both newly diagnosed and previously treated myeloid malignancies.

About Specializations

Kura Oncology Inc. runs clinical trials in conditions such as Acute myeloid leukaemia, Acute myeloid leukaemia recurrent, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziftomenib
  • Sponsor:Kura Oncology Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.